Status and phase
Conditions
Treatments
About
This is a monocentric, prospective, pilot study that will enrol 435 subjects with solid tumours that are treated with immune checkpoint inhibitor(s) (ICI) alone or in combination with chemotherapy or targeted therapy.
For enrolled subjects, clinical and laboratory evaluations will be performed and reported at different time points:
Early (4-6 weeks after treatment start)
Midtime (8-11 weeks after treatment start)
Late (13-18 weeks after treatment start)
At the occurrence of immune-related adverse events (irAEs), clinical and laboratory evaluation will be performed at two principal time points:
Full description
Advances in treating patients with immunotherapy has dramatically changed cancer morbidity and mortality. Immune checkpoint inhibitors (ICI), alone or combined with other drugs, are currently used both as standard of care or in experimental settings for various cancers. Currently, ICI treatment induces objective clinical responses in 20-40% of patients, which varies by tumour type. A significant risk of immune-related adverse events (irAE) is also associated with ICI treatment, including the onset of autoimmune diseases. While the incidence of irAE is highly variable and influenced by many factors, phase I and II trials reported rates from 10% to 80% for any grade irAE while an irAE of grade 3 or higher was observed in 2.5% to 18% of subjects. Despite the fact that older adults represent the growing majority of patients diagnosed with cancer, the efficacy and toxicity of ICI in older patients, alone or in combination with other agents, remains controversial. Presently, the specific immune mechanism(s) driving irAE are unknown and biomarkers that predict their onset, particularly high-grade irAE, are urgently needed. The identification of predictive clinical, laboratory and immunological biomarkers (blood and tissue) for toxicity will more accurately identify and quantify patients who are at risk for ICI therapy. Then, this will possibly allow better irAE management.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Subjects meeting one of the following criteria are not eligible for this study:
Primary purpose
Allocation
Interventional model
Masking
Loading...
Central trial contact
mireille Langouo Fontsa, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal